Skip to main
CATX

CATX Stock Forecast & Price Target

CATX Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Perspective Therapeutics Inc. is positioned favorably within the radiopharmaceutical market, reinforced by promising clinical data indicating that its lead program, VMT-α-NET, has the potential to address a multi-billion-dollar market in neuroendocrine tumors (NET). The use of the alpha-emitting isotope Lead-212 (212Pb) grants the company a competitive edge due to its superior safety and efficacy profile compared to other radioisotopes under development, as evidenced by VMT-α-NET's response rates that significantly outperform Lutathera. Furthermore, the ongoing interest and investments in the radiopharmaceutical space, alongside the encouraging results related to safety and cancer cell targeting, support a strong outlook for Perspective Therapeutics as it continues to advance its pipeline programs.

Bears say

Perspective Therapeutics Inc faces significant commercialization and pricing risks as it attempts to compete in a market with established players struggling with their supply and quality control issues. The company’s reliance on the proprietary Lead-212 technology to deliver treatment could be undermined if it cannot secure favorable pricing or reimbursement rates, particularly when facing stiff competition. Furthermore, the potential for adverse events, such as notable decreases in lymphocyte counts and anemia in clinical trials, raises concerns about the safety profile of its treatments, impacting investor confidence and the overall outlook for the stock.

CATX has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Perspective Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Perspective Therapeutics Inc (CATX) Forecast

Analysts have given CATX a Strong Buy based on their latest research and market trends.

According to 8 analysts, CATX has a Strong Buy consensus rating as of Dec 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Perspective Therapeutics Inc (CATX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.